How naltrexone access changes by country
Start with the exact formulation you are looking for. A country may fund a 50 mg tablet, list only a naltrexone-bupropion product, or use a specialist pathway even when the medicine itself is well established.
A prescription has several moving parts
Finding a regulator entry is only the first step. The exact product may still need a particular prescriber, approval code, pharmacy order, insurer check, or out-of-pocket payment.
The table below is a dated orientation, not a promise of stock or personal eligibility. Use the country page for source links and the questions to take to a clinician, pharmacy, or payer.
Access snapshot by country
Checked 26 July 2026; the New Zealand row was rechecked on 22 October 2026 for Pharmac’s brand change. Each country name opens its guide.
| Country | Standalone oral product | Naltrexone + bupropion | Funding or price | Next check |
|---|---|---|---|---|
| United States | Multiple US generic labels | Contrave | Plan-specific | Coverage and prior authorisation |
| United Kingdom | 50 mg tablet pathway in NICE guidance | Mysimba | Drug Tariff pack price; patient charge varies | Local NHS initiation route |
| Canada | Authorised oral generics; coverage varies | Contrave | Province and plan-specific | Provincial criteria and pharmacy stock |
| Australia | PBS item 8370M | Contrave | PBS maximum co-payment | PBS eligibility and prescriber |
| New Zealand | 50 mg tablets: Naltraccord or Naltrexone-GH; Naltrexone Lupin from 1 November 2026 | Check the current register | Funded under SA1408; other fees may apply | SA1408 eligibility and service fees |
| Singapore | No currently marketed product verified in this review | Contrave SIN16411P | No reliable standalone public price found | Exact product, special supply, and quote |
| South Africa | Naltima 50 mg price record | Contrave | Naltima Single Exit Price | Dispensing fee and stock |
| UAE | Not found in the live EDE search | Contrave active entry | No reliable standalone public price found | Special-supply route for standalone treatment |
Choose the guide that matches where care is delivered
Each page keeps the official record beside the practical next step.
Australia
PBS item and GP route
Canada
Provincial coverage checks
New Zealand
SA1408 and the 1 November brand change
Singapore
Contrave confirmed; standalone uncertain
South Africa
Naltima and Contrave records
United Arab Emirates
Registry and special-supply questions
United Kingdom
NICE and NHS route
United States
Oral, injection, and insurance
Ask four separate questions
This prevents a yes/no answer from hiding the part that affects you.
- Which product? Oral naltrexone, Vivitrol, and Contrave have different purposes and access routes.
- Who starts it? A GP may prescribe in one system while a specialist service initiates treatment in another.
- Who pays? A register, tariff, subsidy, insurer formulary, and final pharmacy bill are different records.
- Who has it today? Only the current supplying service or pharmacy can confirm local stock and timing.
Prepare one precise local question
Name the formulation, treatment purpose, country, and payment route. That will get a more useful answer than asking only whether ‘naltrexone is available’.
Sources
Checked .
- United States: current Vivitrol prescribing information
- United Kingdom: NICE CG115 recommendations
- Canada: Ontario Drug Benefit Formulary results
- Australia: PBS item 8370M
- New Zealand: Pharmac notice on the naltrexone brand change. Last updated 12 October 2026; New Zealand cells rechecked 22 October 2026.
- Singapore: National Drug Formulary naltrexone record
- South Africa: National Department of Health medicine-price records
- UAE: Emirates Drug Establishment Drug Directory